Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study Demonstrates Long-Term Durability of Plicator Procedure

15.01.2007
Patients treated for gastro esophageal reflux disease (GERD) using the endoscopic Plicator procedure show long-term benefits in reducing reflux disease symptoms with no need for long-term prescription antacids, according to a study led by doctors at Beth Israel Deaconess Medical Center (BIDMC).

The majority of patients had complete relief of acid reflux symptoms without the need for prescription proton pump inhibitors and only rare use of antacids according to Douglas Pleskow, MD, the study’s principal investigator.

The findings, appearing in the online edition of the journal Surgical Endoscopy, demonstrate a sustained reduction in GERD symptoms and medication use three years post-procedure. GERD is a condition in which the acidic liquid content of the stomach is regurgitated, causing damage in the lining of the esophagus.

Pleskow says patients suffering from GERD can feel worse than those suffering from depression, heart attacks and even diabetes. “It affects their productivity, their employment so it’s very important to help control gastro esophageal reflux disease.”

The treatment, called endoscopic plication, uses a device called the Plicator to restore the anti-reflux barrier, “a fold over the top part of the stomach that acts to prevent acid and other stomach contents from going up into the esophagus which then reduces symptoms,” says Pleskow.

The study involved 29 patients with chronic heartburn who required daily maintenance of their symptoms with medication. Patients were treated at five sites, each receiving plication treatment. They were then evaluated for GERD symptoms and medication use 12 and 36 months after treatment.

All but one of the 29 patients in the study required daily proton pump therapy prior to the procedure. The other patient was on high dose histamine –2 antagonist therapy. Over half the medication dependant patients remained off the daily treatment at the 36 month follow-up and 50 percent were able to stop medication completely.

Pleskow initially studied the effects of plication in a larger study conducted five years ago with 64 patients. That focused primarily on the efficacy and safety of the device but included a one-year follow-up. It was then determined that a study focusing on the longer-term results of the procedure was necessary. Only 29 of the original 64 original patients were available for long term follow up.

“When we initially looked at the study, there were 59 percent of the patients who had had plication at one year completely symptom free,” Pleskow says. “What the data shows now at three years is that 55 percent of the original patient population had complete symptom relief.”

Pleskow’s goal is to look at the data again in two years. He doesn’t anticipate much drop-off in numbers. In fact with time, he anticipates better results, because this study reflects the early experience of the Plicator. As time has passed the physicians using this device have developed newer techniques at placing the sutures.

“We’re much better at performing the procedure than when we started out and the equipment we’re using now is much more advanced,” Pleskow says, adding he hopes greater availability to the general public will allow for a much larger study in the future.

In addition to Pleskow, study co-authors include BIDMC’s Anthony Lembo, MD, Richard Rothstein, MD, of Dartmouth-Hitchcock Medical Center in Lebanon, NH, Richard Kozarek, MD, of the Virginia Mason Medical Center in Seattle, Gregory Haber, MD, of Lenox Hill Hospital in New York and Christopher Gostout, MD, of the Mayo Clinic in Rochester, MN.

This study was funded by a grant from NDO Surgical, Inc. in Mansfield, MA.

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and ranks third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.harvard.edu.

Zineb Marchoudi | EurekAlert!
Further information:
http://www.bidmc.harvard.edu

More articles from Studies and Analyses:

nachricht Do microplastics harbour additional risks by colonization with harmful bacteria?
05.04.2018 | Leibniz-Institut für Ostseeforschung Warnemünde

nachricht Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Magnetic nano-imaging on a table top

20.04.2018 | Physics and Astronomy

Start of work for the world's largest electric truck

20.04.2018 | Interdisciplinary Research

Atoms may hum a tune from grand cosmic symphony

20.04.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>